Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Non-Current Deffered Revenue: 2015-2018

Historic Non-Current Deffered Revenue for Outlook Therapeutics (OTLK) over the last 4 years, with Sep 2018 value amounting to $2.8 million.

  • Outlook Therapeutics' Non-Current Deffered Revenue rose 15.41% to $3.5 million in Q2 2019 from the same period last year, while for Jun 2019 it was $3.5 million, marking a year-over-year increase of 15.41%. This contributed to the annual value of $2.8 million for FY2018, which is 38.25% down from last year.
  • Outlook Therapeutics' Non-Current Deffered Revenue amounted to $2.8 million in FY2018, which was down 38.25% from $4.5 million recorded in FY2017.
  • Outlook Therapeutics' 5-year Non-Current Deffered Revenue high stood at $12.7 million for FY2015, and its period low was $2.8 million during FY2018.
  • For the 3-year period, Outlook Therapeutics' Non-Current Deffered Revenue averaged around $4.1 million, with its median value being $4.5 million (2017).
  • Data for Outlook Therapeutics' Non-Current Deffered Revenue shows a maximum YoY crashed of 59.51% (in 2016) over the last 5 years.
  • Yearly analysis of 4 years shows Outlook Therapeutics' Non-Current Deffered Revenue stood at $12.7 million in 2015, then slumped by 59.51% to $5.2 million in 2016, then fell by 13.32% to $4.5 million in 2017, then tumbled by 38.25% to $2.8 million in 2018.